1252745

Actelion Pharmaceuticals US Inc. — FEI 3021902393

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
October 28, 2024
Fiscal Year
2025
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Titusville, NJ (United States)

Additional Details

Risk Evaluation and Mitigation Strategies (REMS)

Citations

IDCFRDescription
21355FDCA 505-1(f)(3)(B)Failure to comply with REMS Elements to Assure Safe Use (ETASU) B
21360FDCA 505-1(f)(4)Failure to comply with REMS Implementation System